KRAS and colorectal cancer: These observed exposure values on cycle 1 day 15 of 45 mg binimetinib in combination with different doses of sotrastaurin in this study were consistent with values seen following administration of 45 mg binimetinib as single agent in the dose-expansion phase of the ARRAY-162-111 study in KRAS- and BRAF-mutant colorectal cancer patients (Cmax ranged from 358 to 463 ng/mL and AUC0-8hr ranged from 851 to 2310 hr*ng/mL).